Patent ID: 9321833
Filing Date: 2016-04-26
CPC Classification: A61K,C07K

Claim Text:
1. A method of therapy comprising administering an amount of a humanized anti-CD154 antibody sufficient to suppress CD40/CD154 signaling in a subject in need thereof, wherein the antibody is a humanized anti-CD154 antibody of the IgG1 isotype antibody that comprises a humanized variable light chain polypeptide comprising the V L CDR polypeptides of SEQ ID NO:17, 18 and 19 and the V H CDR polypeptides of SEQ ID NO:24, 25 and 26, wherein the Fc region of said antibody has been mutated to substantially eliminate FcγRII binding and C1Q binding, and further wherein the mutation which substantially eliminates Fcγ RII binding is selected from at least one of a E269R, N325L, and a K326V mutation and the mutation which substantially eliminates complement binding is selected from at least one of K322A, P331G, and P331G/K322A.